Navigation Links
Unigene's Oral PTH Phase 2 Proof-of-Concept Data to be Presented at Upcoming Scientific Conferences
Date:6/28/2012

BOONTON, N.J., June 28, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics, today announced that data from the Company's oral parathyroid hormone (PTH) analog Phase 2 proof-of-concept trial results will be part of two presentations by Dr. Lorraine Fitzpatrick, Medicine Development Leader for GlaxoSmithKline (GSK), at prestigious scientific conferences. 

5th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone Disease

"(Mis)Adventures In Drug Discovery"

  • Date & Time: Thursday, June 28, 2012 at 11:30 a.m. GMT
  • Location:  St. Catherine's College, Oxford, UK
  • Focus: Examination of PTH secretory dynamics via the comparison of PK data from ronacaleret, oral PTH, and PTH 1-34 and 1-84 

GIOSEG 5th Meeting Skeletal Endocrinology

SESSION 4 - Anabolic Therapies for Osteoporosis – "New PTHs: Modalities, Duration, Combinations"

  • Date & Time: Friday, September 21, 2012 from 2:30 - 4:00 p.m. BST
  • Location: University of Brescia, Main Hall School of Medicine, Brescia, Italy
  • Focus: Examination of PTH secretory dynamics via the comparison of PK data from ronacaleret, oral PTH, and PTH 1-34 and 1-84

"We are extremely pleased Dr. Fitzpatrick has chosen to present the data from our oral PTH Phase 2 proof-of-concept trial at two highly prestigious scientific conferences," stated Nozer Mehta, Ph.D., Vice President of Research and Development for Unigene.  "Both presentations will serve to highlight data that strongly validate Unigene's proprietary Peptelligence™ technology and, importantly, that the oral delivery of PTH is technically feasible."

The Phase 2 proof-of-concept oral PTH study was conducted by Unigene
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
2. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
3. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
4. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
5. Ultragenyx Announces Phase 1 Results of UX001 in Hereditary Inclusion Body Myopathy (HIBM), a Rare Neuromuscular Disease
6. Lexicon Receives Funding for Phase 2 Clinical Trial of LX4211 in Type 1 Diabetes
7. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
8. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
9. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
10. Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD
11. Adamas Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for Arimenda™
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) ... Diagnostic Testing Market - Forecasts to 2019: Expected ... and is expected to be valued at USD ... http://photos.prnewswire.com/prnh/20130307/600769 ... segmented according to immunoprotein types which include immunoglobulins, ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... 2014 Yesterday, former Congressman Patrick ... manufacturing facility. Rep. Kennedy and Dick Moberg ... cutting-edge research in neurological disease and treatment. ... advocate, Garen Staglin , created One Mind, ... changes that will radically accelerate the development and ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2Representative Patrick Kennedy visits Moberg's medical device facility to discuss improvement in brain injury care 2
(Date:7/13/2014)... July 13, 2014 Celebrity fitness trainer ... formed a promotional partnership with Aqua Health Labs for ... Omega-3 EPA supplement . The collaboration was recently announced ... fitness trainer , actor, model, and a two ... for A-List celebrities, he has prepared stars including Demi ...
(Date:7/13/2014)... Hope Palliative & Hospice Care announced today ... at the Tamarack Senior Living Community in Palatine, IL. The ... on the 3rd Wednesdays of every month. This group ... Community located at 55 S. Greeley St. Palatine, IL 60067. ... is no cost for the group. , “A grief ...
(Date:7/13/2014)... According to The Peripheral Neuropathy Program review ... that teaches people how to deal with diabetic nerve ... This program also provides people with safe and effective ... including numbness, prickling, burning, and intense stabbing pains. ... treatment program can help people eliminate some types of ...
(Date:7/13/2014)... Recently, iFitDress.com, one of the most popular suppliers of ... a new selection of beautiful evening dresses ... promotion for these evening gowns. Now, everybody can enjoy ... thousands of graceful gowns in its online store. Most ... Italy and many other countries. They are highly appreciated ...
(Date:7/12/2014)... 13, 2014 Recently, Fadhits.com, a well-known wedding ... elegant long graduation dresses to its product line. ... its loyal clients. It wants to bring more benefits for ... now offered at discounted prices, up to 72% off. , ... always working hard. Its online shop is a good place ...
Breaking Medicine News(10 mins):Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Hope Hospice Announces Grief Support Group at the Tamarack Senior Living Community 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3Health News:New and Beautiful Evening Dresses Unveiled by iFitDress.com 2Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2
... Life-DaVita Medical Missions, program reaches out to patients in ... need of care ... program is being recognized as life-saving by 16 year-old,Juan Carlos and his ... for survival and was just days away from dying.,This past December, DaVita ...
... studies finds regimen popular in 1980s doesn,t really lengthen ... chemotherapy has only a minimal effect on survival in ... , "It,s pretty clearly established that [high-dose chemotherapy] is ... of the Division of Quantitative Sciences at the University ...
... The fifth annual Gastrointestinal Cancers Symposium is a three-day ... on the latest clinical strategies for the prevention, screening ... are expected to gather at this years Symposium which ... Friday, January 25 Sunday, January 27, 2008, WHERE:, ...
... and Leicester are collaborating in the use of a ... spaces inside the lungs and the results of ... disease and later degenerative lung disease. , There are ... to this particular magnetic resonance technique, which is based ...
... Boston, MAMichael F. Holick, PhD, MD, was recently awarded ... Society of Endocrinology and Metabolism (CSEM). Holick, an ... received the award for decades of pioneering work that ... wide variety of chronic health conditions. , ...
... A clinical study conducted at Henry Ford Hospital on ... patients with the most common and aggressive type of brain ... , The randomized Phase II study focused on patients ... or second-line therapy. The study revealed that more than a ...
Cached Medicine News:Health News:16-Year-Old Ecuadorian Boy in Dire Need of Dialysis Treatments Thanks One of Nation's Leading Providers for Saving His Life 2Health News:16-Year-Old Ecuadorian Boy in Dire Need of Dialysis Treatments Thanks One of Nation's Leading Providers for Saving His Life 3Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 2Health News:High-Dose Chemo Provides Little Benefit to Breast Cancer Patients 3Health News:New technique reveals insights into lung disease 2Health News:Boston University Medical Center researcher honored 2Health News:Drug study for brain cancer shows promising results 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: